150 related articles for article (PubMed ID: 6381432)
1. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
2. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
3. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
[TBL] [Abstract][Full Text] [Related]
4. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
5. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
6. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
7. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
Mitchell JB; Russo A; Kinsella TJ; Glatstein E
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1513-8. PubMed ID: 3531118
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
[TBL] [Abstract][Full Text] [Related]
9. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
[TBL] [Abstract][Full Text] [Related]
10. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
[TBL] [Abstract][Full Text] [Related]
11. [Radiation sensitization of brain neoplasms by haloid analogs of pyrimidine bases].
Lokshina AM; Pelevina II
Med Radiol (Mosk); 1973 Mar; 18(3):70-7. PubMed ID: 4267617
[No Abstract] [Full Text] [Related]
12. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.
Kinsella TJ; Dobson PP; Mitchell JB; Fornace AJ
Int J Radiat Oncol Biol Phys; 1987 May; 13(5):733-9. PubMed ID: 3570896
[TBL] [Abstract][Full Text] [Related]
14. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
Rodriguez R; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
[No Abstract] [Full Text] [Related]
15. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of radiation sensitizing agents.
Goffinet DR; Bagshaw MA
Cancer Treat Rev; 1974 Mar; 1(1):15-26. PubMed ID: 4143475
[No Abstract] [Full Text] [Related]
17. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
Matsutani M; Kohno T; Nagashima T; Nagayama I; Matsuda T; Hoshino T; Sano K
Radiat Med; 1988; 6(1):33-9. PubMed ID: 3045898
[TBL] [Abstract][Full Text] [Related]
18. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR.
Mitchell JB; Morstyn G; Russo A; Kinsella TJ; Fornace A; McPherson S; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1447-51. PubMed ID: 6469768
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.
Greenberg HS; Chandler WF; Ensminger WD; Sandler H; Junck L; Page MA; Crane D; McKeever P; Tankanow R; Bromberg J
Neurology; 1994 Sep; 44(9):1715-20. PubMed ID: 7936303
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers.
Kinsella TJ
Semin Oncol; 1992 Jun; 19(3 Suppl 9):41-7. PubMed ID: 1641656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
